BRAF inhibitor:a novel therapy for ameloblastoma in mandible  

作　　者：Masanobu Abe Liang Zong Takahiro Abe Hideyuki Takeshima Jiafu Ji Toshikazu Ushijima Kazuto Hoshi 

机构地区：[1]Department of Oral & Maxillofacial Surgery,University of Tokyo Hospital [2]Division for Health Service Promotion,University of Tokyo [3]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Center of Gastrointestinal Surgery,Peking University Cancer Hospital & Institute [4]Graduate School of Medicine,University of Tokyo [5]Division of Epigenomics,National Cancer Center Research Institute

出　　处：《Chinese Journal of Cancer Research》2018年第6期677-678,共2页中国癌症研究（英文版）

摘　　要：Ameloblastoma is a benign but locally aggressive odontogenic neoplasm that accounts for 10% of all tumors arising in the mandible and maxilla (1). Eighty percent of ameloblastomas arise in the mandible, and they are usually found in young adults. It frequently recurs if not adequately

关 键 词：BRAF inhibitor:a novel therapy for ameloblastoma in mandible 

分 类 号：R[医药卫生]